Tumor vessel normalization and immunotherapy in gastric cancer. (July 2022)

• Record Type: Journal Article
• Authors: Yu, Xianzhe; He, Shan; Shen, Jian; Huang, Qiushi; Yang, Peng; Huang, Lin; Pu, Dan; Wang, Li; Li, Lu; Liu, Jinghua; Liu, Zelong; Zhu, Lingling
• Is Part Of: Therapeutic advances in medical oncology. Volume 14(2022)
• Publication Date: 2022-07
• Subjects: gastric cancer -- immune checkpoint inhibitors -- immune microenvironment -- immunotherapy -- vessel normalization; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/17588359221110176
• Languages: English
• ISSNs: 1758-8340

Abstract

Gastric cancer (GC) is a common malignant tumor, and patients with GC have a low survival rate due to limited effective treatment methods. Angiogenesis and immune evasion are two key processes in GC progression, and they act synergistically to promote tumor progression. Tumor vascular normalization has been shown to improve the efficacy of cancer immunotherapy, which in turn may be improved through enhanced immune stimulation. Therefore, it may be interesting to identify synergies between immunomodulatory agents and anti-angiogenic therapies in GC. This strategy aims to normalize the tumor microenvironment through the action of the anti-vascular endothelial growth factor while stimulating the immune response through immunotherapy and prolonging the survival of GC patients.